Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 4
Submit an article Journal homepage
157
Views
54
CrossRef citations to date
0
Altmetric
Review

Novel approaches to the pharmacological blockade of gastric acid secretion

Michael E Parsons University of Hertfordshire, Department of Biosciences, Hatfield, Hertfordshire AL10 9AB, UK. [email protected]
&
David J Keeling AstraZeneca R&D Charnwood, Lead Generation Biology, Molecular Biology, Bakewell Road, Loughborough, Leics LE11 5RH, UK. [email protected]
Pages 411-421 | Published online: 22 Apr 2005

Bibliography

  • VAN PINXTEREN B, NUMANS ME, LAU J, DE WIT NJ, HUNGIN AP, BONIS PA: Short-term treatment of gastroesophageal reflux disease. J. an. Intern. Med. (2003) 18:755–763.
  • CHIBA N, DE GARA CJ, WILKINSON JM, HUNT RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 112:1798–1810.
  • CRAWLEY JA, SCHMITT CM: How satisfied are chronic heartburn suffers with their prescription medications? Results of the patient unmet needs survey. J. Clin. Outcomes Management (2000) 7:29–34.
  • ANDERSSON T: Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. (1996) 31:9–28.
  • TONINI M, GIORGIO RD, PONTI FD:Novel therapeutic strategies in acid-related disorders. Expert Opin. Ther. Targets (2003) 13:639–649.
  • KIL BJ, KIM IW, SHIN CY et al: Comparison of IY81149 with omeprazole in rat reflux oesophagitis. Auton. Pharmacol. (2000) 20:291–296.
  • DOMAGALA F, FICHEUX H: Pharmacokinetics of tenatoprazole, a novel proton pump inhibitor, in healthy male caucasian volunteers. Gastroenterology (2003) 124:S1608 (Abstract).
  • GALMICHE JP, BRULEY DV, DUCROTTE P et al.: Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment. Pharmacol. Ther. (2004) 19:655–662.
  • TONINI M, DE GIORGIO R, DE PONTI F: Progress with novel pharmacological strategies for gastro-oesophageal reflux disease. Drugs (2004) 64:347–361.
  • DAJANI EZ, KLAMUT MJ: Novel therapeutic approaches to gastric and duodenal ulcers: an update. Expert. Opin. Investig. Drugs (2000) 9:1537–1544.
  • VAKIL N: New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment. Pharmacol Ther. (2004) 19:1–9.
  • ••An important paper that provides anoverview of a number of new drug groups that may represent the future medical therapy for GORD.
  • BLACK JW, DUNCAN WA, DURANT CJ, GANELLIN CR, PARSONS EM: Definition and antagonism of histamine H2 receptors. Nature (1972) 236:385–390.
  • ••An important paper on the discovery of1–12 receptors.
  • CORUZZI G, MORINI G, ADAMI M, GRANDI D: Role of histamine H3 receptors in the regulation of gastric functions. J. Physiol Pharmacol. (2001) 52:539–553.
  • PRINZ C, KAJIMURA M, SCOTT DR, MERCIER F, HELANDER HF, SACHS G: Histamine secretion from rat enterochromaffin like cells. Gastroenterology (1993) 105:449–461.
  • KIDD M, TANG LH, MIU K, LAWTON GP, SANDORA, MODLIN IM: Autoregulation of enterochromaffin-like cell histamine secretion via the histamine 3 receptor subtype. Yale J. Biol. Med. (1996) 69:9–19.
  • HOLLANDE F, BALI JP, MAGOUS R: Autoregulation of histamine synthesis through H3 receptors in isolated fundic mucosal cells. Am. Physic] (1993) 265:G1039–G1044.
  • BADO A, MOIZO L, LAIGNEAU JP, LEWIN MJ: Pharmacological characterization of histamine H3 receptors in isolated rabbit gastric glands. Am. Physic] (1992) 262:G56–G61.
  • LINDSTROM E, BJORKQVIST M, BOKETOFT A et al.: Neurohormonal regulation of histamine and pancreastatin secretion from isolated rat stomach ECL cells. Regal. Pept. (1997) 71:73–86.
  • YOKOTANI K, MURAKAMI Y, OKADA S, WANG M, NAKAMURA K: Histamine H(3) receptor-mediated inhibition of endogenous acetylcholine release from the isolated, vascularly perfused rat stomach. Eur. Pharmacol (2000) 392:23–29.
  • BADO A, LAIGNEAU JP, MOIZO L, CHERIFI Y, LEWIN MJ: H3-receptor activation inhibits cholinergic stimulation of acid secretion in isolated rabbit fundic glands. I Pharmacol Exp. Ther. (1995) 275:1099–1103.
  • CORUZZI G, ADAMI M, BERTACCINI G: Histamine H3 receptors are not involved in the regulation of rat gastric secretion. Pharmacology (1992) 44:190–195.
  • VUYYURU L, SCHUBERT ML: Histamine, acting via H3 receptors, inhibits somatostatin and stimulates acid secretion in isolated mouse stomach. Gastroenterology (1997) 113:1545–1552.
  • CORUZZI G, BERTACCINI G, SCHWARTZ JC: Evidence that histamine H3 receptors are involved in the control of gastric acid secretion in the conscious cat. Naunyn Schmiedebergs. Arch. Pharmacol (1991) 343:225–227.
  • BADO A, HERVATIN F, LEWIN MJ: Pharmacological evidence for histamine H3 receptor in the control of gastric acid secretion in cats. Am. J. Physic] (1991) 260:G631–G635.
  • •A key paper that investigates the Involvement of the H3 receptor in the control of gastric acid secretion.
  • BAROCELLI E, BALLABENI V, CHIAVARINI M, IMPICCIATORE M: R-a-methylhistamine-induced inhibitionof gastric acid secretion in pylorus-ligatedrats via central histamine H3 receptors. BEPharmacol. (1995) 115:1326–1330.
  • BALLABENI V, CALCINA F, BOSETTI M et al.: Different role of the histamine H3-receptor in vagal-, betanechol-, pentagastrin-induced gastric acid secretion in anaesthetized rats. Scand. Gastroenterol. (2002) 37:754–758.
  • SOLDANI G, MENGOZZI G, INTORRE L, DE GIORGI G, CORUZZI G, BERTACCINI G: Histamine H3 receptor-mediated inhibition of gastric acid secretion in conscious dogs. Naunyn Schmiedebergs. Arch. Pharmacol (1993) 347:61–65.
  • SOLDANI G, GARBARG M, INTORRE L, BERTINI S, ROULEAU A, SCHWARTZ JC: Modulation of pentagastrin-induced histamine release by histamine H3 receptors in the dog. Scand. Gastroenterol. (1996) 31:631–638.
  • •A key paper that examines the control of acid secretion by the H3 receptor.
  • SOLDANI G, INTORRE L, BERTINI S, LUCHETTI E, CORUZZI G, BERTACCINI G: Regulation of gastric acid secretion by histamine H3 receptors in the dog: an investigation into the site of action. Naunyn Schmiedebergs. Arch. Pharmacol. (1994) 350:218–223.
  • ROULEAU A, GARBARG M, LIGNEAU X et al.: Bioavailability, antinociceptive and antiinflammatory properties of BP 2-94, a histamine H3 receptor agonist prodrug. Pharmacol Exp. Ther. (1997) 281:1085–1094.
  • STARK H, KRAUSE M, ROULEAU A, GARBARG M, SCHWARTZ JC, SCHUNACK W: Enzyme-catalyzed prodrug approaches for the histamine H3-receptor agonist N-a-methylhistamine. Bioorg. Med. Chem. (2001) 9:191–198.
  • KRAUSE M, STARK H, SCHUNACK W: Azomethine prodrugs of (R)-a-methylhistamine, a highly potent and selective histamine H3-receptor agonist. Curr. Med. Chem. (2001) 8:1329–1340.
  • SOLDANI G, BERTINI S, ROULEAU A, SCHWARTZ JC, CORUZZI G: Gastric antisecretory effects of compound BP 2-94: a histamine H3-receptor agonist prodrug. Dig. Dis. Sci. (1999) 44:2380–2385.
  • ••A key paper that confirms the mainmechanism underlying the inhibition of acid production induced by H3 receptor activation.
  • FOZARD JR: BP-294 Ste Civile Bioprojet. Curr. Opin. Investig. Drugs (2000) 1:86–89.
  • BLAIR AJ III, RICHARDSON CT, WALSH JH, FELDMAN M: Variable contribution of gastrin to gastric acid secretion after a meal in humans. Gastroenterology (1987) 92:944–949.
  • KIDD M, MODLIN IM, TANG LH: Gastrin and the enterochromaffin-like cell: an acid update. Dig. &mg. (1998) 15:209–217.
  • HOLST JJ, KNUHTSEN S, ORSKOV C, SKAK-NIELSEN T, POULSEN SS, NIELSEN OV: GRP-producing nerves control antral somatostatin and gastrin secretion in pigs. Am. J. Physic] (1987) 253:G767–G774.
  • PRINZ C, SCOTT DR, HURWITZ D, HELANDER HF, SACHS G: Gastrin effects on isolated rat enterochromaffin-like cells in primary culture. Am. Physic] (1994) 267:G663–G675.
  • KOPIN AS, LEE YM, McBRIDE EW et al.: Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc. Natl. Acad. Sci. USA (1992) 89:3605–3609.
  • SOLL AH, AMIRIAN DA, THOMAS LP, REEDY TJ, ELASHOFF JD: Gastrin receptors on isolated canine parietal cells. Clin. Invest. (1984) 73:1434–1447.
  • NOBLE F, WANK SA, CRAWLEY JN et al.: International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev (1999) 51:745–781.
  • SAND VIK AK, WALDUM HL: CCK-B(gastrin) receptor regulates gastric histamine release and acid secretion. Am. Physic] (1991) 260:G925–G928.
  • CHEY WY, SIVASOMBOON B, HENDRICKS J: Actions and interactions of gut hormones and histamine on gastric secretion of acid in the rat. Am. J. Physic] (1973) 224:852–856.
  • •A key paper describing histamine and gastric acid secretion.
  • KAMINSKI DL, RUWART MJ, JELLINEK M: Structure-function relationships of peptide fragments of gastrin and cholecystokinin. Am. J. Physic] (1977) 233:E286–E292.
  • DELVALLE J, CHIBA T, PARK J, YAMADA T: Distinct receptors for cholecystokinin and gastrin on canine fundic D-cells. Am. J. Physic] (1993) 264:G811–G815.
  • NISHIDA A, MIYATA K, TSUTSUMI R et al.: Pharmacological profile of (A -1-12,3-dihydro-1-(2'-methylphenacy1)-2-oxo- 5-pheny1-1H-1,4-benzodiazepin-3-y11-3-(3-methylphenyOurea (YM022), a new potent and selective gastrin/ cholecystokinin-B receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. (1994) 269:725–731.
  • NISHIDA A, TAKINAMI Y, YUKI H et al: YM022 ag -1- (2, 3-dihydro- 1 - [2'-methylphenacy1]-2-oxo-5-phenyl-1H-1,4-benzodiazepin 3 yl) 3 [3 methylphenyl]urea), a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. .1 Pharmacol. Exp. Ther. (1994) 270:1256–1261.
  • PENDLEY CE, FITZPATRICK LR, CAPOLINO AJ et al: RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat../. Pharmacol. Exp. Ther. (1995) 273:1015–1022.
  • TAKEUCHI K, HIRATA T, YAMAMOTO H, KUNIKATA T, ISHIKAWA M, ISHIHARA Y: Effects of S-0509, a novel CCKB/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in rats. Aliment. Pharmacol Ther. (1999) 13:87–96.
  • AMAGASE K, IKEDA K, OKABE S: Antisecretory and ulcer healing effects of S-0509, a novel CCK-B/gastrin receptor antagonist, in rats. Dig. Dis. Sci. (1999) 44:879–888.
  • STEEL K: Gastrin and gastrin receptor ligands - a review of recent patent literature. 'Drugs (2002) 5:689–695.
  • BELTINGER J, HILDEBRAND P, DREWE J et al.: Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans. Eur..1. Clin. Invest. (1999) 29:153–159.
  • BASTAKI SM, HASAN MY, CHANDRANATH SI, SCHMASSMANN A, GARNER A: PD-136450: a CCK2 (gastrin) receptor antagonist with antisecretory, anxiolytic and antiulcer activity. Mol. Cell Biochem. (2003) 252:83–90.
  • MAKOVEC F, D'AMATO M: CCKB/ gastrin receptor antagonists as potential drugs for peptic ulcer therapy. Drug Disco v. Today (1997) 7:283–293.
  • ••A key paper that provides an overview ofgastrin receptor antagonists.
  • MIURA N, YONETA T, UKAWA H et al.: Pharmacological Profiles of Z-360, a Novel CCK/Gastrin (CCK2) Receptor Antagonist with Excellent Oral Potency. Gastroenterology (2001) 120:A311 (Abstract).
  • MORITA H, MIURA N, HORI Y et al.: Effects of Z-360, a novel CCKB/gastrin (CCK2) receptor antagonist, on meal-induced acid secretion and experimental ulcer models in dogs and rats. Gastroenterology (2001) 120:A311 (Abstract).
  • MAKOVEC F, REVEL L, LETARI 0, MENNUNI L, IMPICCIATORE M: Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist. Eur..1. Pharmacol (1999) 369:81–90.
  • BLACK JW, KALINDJIAN SB: Gastrin agonists and antagonists. Pharmacol Toxicol (2002) 91:275–281.
  • GANSER AL, FORTE JG: 1('-stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochim. Biophys. Acta. (1973) 307:169–180.
  • ••A key paper that identified the HVI('-ATPase as the primary gastric enzyme of II' secretion.
  • METZ DC, FERRON GM, PAUL J et al: Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study. J. Clin. Pharmacol. (2002) 42:512–519.
  • YAO X, FORTE JG: Cell biology of acid secretion by the parietal cell. Ann. Rev Physic] (2003) 65:103–131.
  • •A key paper that summarises the progress made toward an understanding of the cell biology of gastric acid secretion.
  • GRAHAMMER F, HERLING AW, LANG HJ et al.: The cardiac K.* channel KCNQ1 is essential for gastric acid secretion. Gastroenterology (2001) 120:1363–1371.
  • DEDEK K, WALDEGGER S: Colocalization of KCNQl/KCNE channel subunits in the mouse gastrointestinal tract. Pllugers Arch. (2001) 442:896–902.
  • FUJITA A, HORIO Y, HIGASHI K et al:Specific localization of an inwardly rectifying K(') channel, Kir4.1, at the apical membrane of rat gastric parietal cells; its possible involvement in KO recycling for the H(1-K(1-pump. J. Physic] (2002) 540:85–92.
  • MALINOWSKA DH, SHERRY AM, TEWARI KP, CUPPOLETTI J: Gastric parietal cell secretory membrane contains PKA- and acid-activated Kir2.1 channels. Am. J. Physic] Cell. Physic] (2004) 286:C495–0506.
  • SHERRY AM, MALINOWSKA DH, MORRIS RE, CIRAOLO GM, CUPPOLETTI J: Localization of C1C-2 Cl-channels in rabbit gastric mucosa. Am. J. Physic] Cell. Physic] (2001) 280:C1599–C1606.
  • SAKAI H, OKADA Y, MORII M, TAKEGUCHI N: Anion and cation channels in the basolateral membrane of rabbit parietal cells. Pllugers. Arch. (1989) 414:185–192.
  • SUPPLISSON S, LOO DD, SACHS G: Diversity of K.' channels in the basolateral membrane of resting Necturus oxyntic cells. .1 Membr. Biol. (1991) 123:209–221.
  • POST RL, HEGYVARY C, KUME S: Activation by adenosine triphosphate in the phosphorylation kinetics of sodium and potassium ion transport adenosine triphosphatase. ./. Biol. Chem. (1972) 247:6530–6540.
  • ••A historic paper.
  • ALBERS R: Biochemical aspects of active transport. Ann. Rev Biochem. (1967) 36:727–756.
  • ••A historic paper.
  • KUHLBRANDT W: Biology, structure and mechanism of P-type ATPases. Nat. Rev Mol..Cell. Biol. (2004) 5:282–295.
  • •An elegant and recent review summarising the biology of ATPase.
  • WALLMARK B, STEWART HB, RABON E, SACCOMANI G, SACHS G. The catalytic cycle of gastric (H-11(1-ATPase. J. Biol. Chem. (1980) 255:5313–5319.
  • ••An important paper describing thereaction sequence of gastric
  • SWARTS HG, KLAASSEN CH, DE BOER M, FRANSEN JA, DE PONT JJ: Role of negatively charged residues in the fifth and sixth transmembrane domains of the catalytic subunit of gastric FP/K.'-ATPase../. Biol. Chem. (1996)271:29764–29772.
  • VAGIN 0, MUNSON K, LAMBRECHT N, KARLISH SJ, SACHS G: Mutational analysis of the K* competitive inhibitor site of gastric H/K-ATPase. Biochemistry (2001) 40:7480–7490.
  • ASANO S, TEGA Y, KONISHI K, FUJIOKA M, TAKEGUCHI N: Functional expression of gastric FIVIc(1-ATPase and site-directed mutagenesis of the putative cation binding site and catalytic center. J. Biol. Chem. (1996) 271:2740–2745.
  • KOENDERINK JB, SWARTS HG, WILLEMS PH, KRIEGER E, DE PONT JJ: A conformation-specific interhelical salt bridge in the K.' binding site of gastric H/K-ATPase. .1 Biol. Chem. (2004) 279:16417–16424.
  • KEELING DJ, LAING SM, SENN-BILFINGER J: SCH 28080 is a lumenally acting, K+-site inhibitor of the gastric (HV Kl-ATPase. Biochem. Pharmacol (1988) 37:2231–2236.
  • WALLMARK B, BRIVING C, FRYKLUND J et al.: Inhibition of gastric FIVIc+-ATPase and acid secretion by SCH 28080, a substituted pyridy1(1,2a)imidazole. J. Biol. Chem. (1987) 262:2077–2084.
  • VAGIN 0, DENEVICH S, MUNSON K, SACHS G: 5CH28080, a K*-competitive inhibitor of the gastric H/K-ATPase, binds near the M5-6 luminal loop, preventing K.' access to the ion binding domain. Biochemistry (2002) 41:12755–12762.
  • VAGIN 0, MUNSON K, DENEVICH S, SACHS G: Inhibition kinetics of the gastric H/K-ATPase by K-competitive inhibitor 5CH28080 as a tool for investigating the luminal ion pathway. Ann. NY Acad. Sci. (2003) 986:111–115.
  • KEELING DJ, TAYLOR AG, SCHUDT C: The binding of a K.+ competitive ligand, 2-methy1,8-(phenylmethoxy)imidazo(1,2-a)pyridine 3-acetonitrile, to the gastric (FIVIcl-ATPase. J. Biol. Chem. (1989)264:5545–5551.
  • ASANO S, YOSHIDA A, YASHIRO H et al.: The cavity structure for docking the KO-competitive inhibitors in the gastric proton pump. J. Biol. Chem. (2004)279:13968–13975.
  • BESANCON M, SIMON A, SACHS G, SHIN JM: Sites of reaction of the gastric H/K-ATPase with extracytoplasmic thiol reagents. .1 Biol. Chem. (1997) 272:22438–22446.
  • MORII M, TAKEGUCHI N: Different biochemical modes of action of two irreversible RiK(÷)-ATPase inhibitors, omeprazole and E3810. j. Biol. Chem. (1993) 268:21553–21559.
  • ENE MD, KHAN-DANESHMEND T, ROBERTS CJ: A study of the inhibitory effects of SCH 28080 on gastric secretion in man. BE J. Pharmacol (1982) 76:389–391.
  • MARTINEK J, BLUM AL, STOLTE M et al.: Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment. Pharmacol Ther. (1999) 13:27–34.
  • POPE AJ, PARSONS ME: Reversible inhibitors of the gastric FT-A((0-transporting ATPase: a new class of anti-secretory agent. Trends Pharmacol Sri. (1993) 14:323–325.
  • PARKS, AHN B, LEE B, KANG H, SONG K: Pharmacokinetics of YH1885. Gut (2003) 52(Suppl. VI):IVION-G-008 (Abstract).
  • PARKS, LEES, SONG K, LEE B, KANG H, KANG J: The pharmacological properties of a novel acid pump antagonist, YH1885. Gut (2003)52(Suppl. VI):MON-G-009 (Abstract).
  • YU KS, BAE KS, SHON JH ET AL.: Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. Pharmacol (2004) 44:73–82.
  • BRIVING C, SVENSSON K, MAXVALL I, ANDERSSON K: Mechanism of action of AZD-0865, an FIVIc+-ATPase selective, potassium-competitive acid blocker. Gastroenterology (2004) 126:A-333 (Abstract M1436).
  • HOLSTEIN B, HOLMBERG A, FLORENTZSON M, AURELL HOLMBERG A, ANDERSSON M, ANDERSSON K: AZD0865 - a new potassium-competitive acid blocker exhibits maximal gastric antisecretory effects from first dose. Gastroenterology (2004) 126:A-334 (Abstract M1437).
  • HOLSTEIN B, HOLMBERG A, FLORENTZSON M, AURELL HOLMBERG A, ANDERSSON M, ANDERSSON K: Pharmacokinetic and pharmacodynamic profiles of AZD0865, a novel, potassium-competitive acid blocker. Gastroenterology (2004) 126:A-334 (Abstract M1440).
  • ANDERSSON K, AURELL HOLMBERG A, BRIVING C, HOLSTEIN B: Preclinical profile of AZD0865, a novel, selective, potassium-competitive acid blocker. Gastroenterology (2004) 126:A-56 (Abstract 448).
  • HOLSTEIN, B, FLORENTZSON M, ANDERSSON M, ANDERSSON K: AZD-0865, a potassium-competitive acid blocker (P-CAB), has a long duration of effect in the rat. Am. Gastroenterol (2004) 99\(Suppl. 10):58 (Abstract 22).
  • ITO K, KINOSHITA K, TOMIZAWA A et al: The anti-secretory and anti-ulcer properties of R-105266, a novel acid pump antagonist. Gut (2001)49 (Suppl. III):(Abstract 3061).
  • POPE AJ, SACHS G: Reversible inhibitorsof the gastric (FIVIcl-ATPase as both potential therapeutic agents and probes of pump function. Biochem. Soc. Trans. (1992) 20:566–572.

Website

  • http://www.rotta.com/cr2945.htm Rottapharm R&D (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.